A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanqiong, Mao, Xia, Chen, Wenjia, Guo, Xiaodong, Yu, Liangxiang, Jiang, Funeng, Wang, Xiaoyue, Li, Weijie, Guo, Qiuyan, Li, Taixian, Lin, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994416/
https://www.ncbi.nlm.nih.gov/pubmed/31982775
http://dx.doi.org/10.1016/j.omtn.2019.12.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994416/
https://www.ncbi.nlm.nih.gov/pubmed/31982775
http://dx.doi.org/10.1016/j.omtn.2019.12.023

Ejemplares similares